A PHASE 2, OPEN-LABEL, SINGLE-ARM, PROSPECTIVE, MULTICENTER STUDY OF NAB-SIROLIMUS PLUS LETROZOLE IN ADVANCED OR RECURRENT ENDOMETRIOID ENDOMETRIAL CANCER

被引：0
|
作者：
Dockery, Lauren [1 ]
Musa, Fernanda [2 ]
Mathews, Cara [3 ]
Spirtos, Nick [4 ]
Slomovitz, Brian [5 ,6 ]
Priebe, Anna [7 ]
Green, Angela [8 ]
Puechl, Allison [9 ]
Birrer, Michael [10 ]
Herzog, Thomas [11 ]
Ding, Li [12 ]
Schmid, Anita [12 ]
Navarro, Willis [12 ]
Moore, Kathleen [13 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[2] Swedish Canc Inst, Seattle, WA USA
[3] Women & Infants Hosp Rhode Isl, Providence, RI USA
[4] Womens Canc Ctr Nevada, Las Vegas, NV USA
[5] Florida Int Univ, Mt Sinai Med Ctr, Dept Gynecol Oncol, Miami Beach, FL USA
[6] Florida Int Univ, Dept Obstet & Gynecol, Miami Beach, FL USA
[7] Texas Oncol, Ft Worth, TX USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Atrium Hlth, Charlotte, NC USA
[10] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR USA
[11] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA
[12] Aadi Biosci, Pacific Palisades, CA USA
[13] Oklahoma Univ Hlth, Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.606
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TP004/#156
引用
收藏
页码：A348 / A348
页数：1
相关论文
共 50 条
  • [21] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [22] Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study
    Wang, Xipeng
    Li, Jiarui
    Zhang, Ping
    Wang, Yizhi
    Lu, Xin
    Xu, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [24] Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)
    Ozeki, Michio
    Asada, Ryuta
    Saito, Akiko M.
    Hashimoto, Hiroya
    Fujimura, Takumi
    Kuroda, Tatsuo
    Ueno, Shigeru
    Watanabe, Shoji
    Nosaka, Shunsuke
    Miyasaka, Mikiko
    Umezawa, Akihiro
    Matsuoka, Kentaro
    Maekawa, Takanobu
    Yamada, Yohei
    Fujino, Akihiro
    Hirakawa, Satoshi
    Furukawa, Taizo
    Tajiri, Tatsuro
    Kinoshita, Yoshiaki
    Souzaki, Ryota
    Fukao, Toshiyuki
    REGENERATIVE THERAPY, 2019, 10 : 84 - 91
  • [25] A prospective, open-label, single-arm study to evaluate the efficacy of dydrogesterone in the treatment of endometrial polyps
    Chen, Qian
    Zhang, Da
    Wang, Shu
    Lang, Jing-He
    Chao, Xiao-Pei
    Fan, Qing-Bo
    GYNECOLOGICAL ENDOCRINOLOGY, 2021, 37 (02) : 152 - 156
  • [26] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [27] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [28] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Andrea Necchi
    Salvatore Lo Vullo
    Luigi Mariani
    Daniele Raggi
    Patrizia Giannatempo
    Giuseppina Calareso
    Elena Togliardi
    Flavio Crippa
    Nicola Di Genova
    Federica Perrone
    Maurizio Colecchia
    Biagio Paolini
    Giuseppe Pelosi
    Nicola Nicolai
    Giuseppe Procopio
    Roberto Salvioni
    Filippo G. De Braud
    Investigational New Drugs, 2016, 34 : 236 - 242
  • [29] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Necchi, Andrea
    Lo Vullo, Salvatore
    Mariani, Luigi
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Di Genova, Nicola
    Perrone, Federica
    Colecchia, Maurizio
    Paolini, Biagio
    Pelosi, Giuseppe
    Nicolai, Nicola
    Procopio, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 236 - 242
  • [30] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
12345